INS and type 2 diabetes mellitus: In advanced T2D, both subcutaneous semaglutide (0.5 mg and 1.0 mg) and oral semaglutide (7 mg and 14 mg) reduced body weight significantly more than placebo in patients inadequately controlled on insulin (p < 0.001) (Figure 2D) (20, 26).